Bobby W. Sandage, Jr., Ph.D.
President & Chief Executive Officer
Dr. Sandage has over 30 years of experience in the pharmaceutical industry. He has been President and CEO of Euclises Pharmaceuticals, Inc. since January 2015. Previously he was President and Chief Executive Officer for Coronado BioSciences, Inc. (CNDO) where he led the effort to take the company public 2011. Prior to that, he was vice president of Covidien (Mallinckrodt) Pharmaceuticals’ oncology research and development program. For 19 years, Dr. Sandage was the Chief Scientific Officer and Executive Vice President of research and development, quality and manufacturing at Indevus Pharmaceuticals, which was acquired by Endo Pharmaceuticals in 2009. Prior Indevus he held senior drug development positions at DuPont Merck Pharmaceutical Company, DuPont/American Critical Care, Merrell Dow and Dow Pharmaceuticals.
Dr. Sandage is currently a director and chairman of Immunophotonics, a private oncology company and director at EDIS Solutions (a data analysis company for the pharmaceutical industry). Previously he was director of Vasculox (private oncology company) and director and chairman of the Scientific Committee of the Italian biotech company, Gentium (GENT). He was director and member of the audit committee for Osteologix, Inc. (OLGX), a director and a member of the audit committee of Genta Inc. (GNTA) and a director for the privately held company, Aeolus Pharmaceuticals, which was a subsidiary of Incara Pharmaceuticals.
John Talley, Ph.D.
Chief Scientific Officer
Dr. John Talley, a co-founder of Euclises, brings over thirty years experience and a record as one of the world’s most successful medicinal chemists. He is best known as the co-inventor of the blockbuster COX-2 inhibitor celecoxib (Celebrex®) and follow-on coxibs Bextra® and Dynastat®. In addition, John played a major role in the discovery of the HIV protease inhibitors Agenerase®, Lexiva®, and Prezista®. In all, he is a co-inventor of seven marketed drugs, with several more still in development. He previously served as Senior Vice President at Ironwood Pharmaceuticals and in various roles at G. D. Searle and Pharmacia. He is a named inventor on more than 215 issued U.S. drug patents, authored over 50 peer reviewed publications, and has been honored with the prestigious PhRMA Discoverers Award in 2002.
Kathleen Larrimer Beckmann, M.B.A.
Chief Financial Officer
Kathleen Beckmann brings twenty years experience in finance, project management, and business development. She has expertise in operations, marketing, strategic planning, and training, as well as experience in the healthcare sector. Previously, Kathleen worked in product management and financial analysis in the consumer banking industry.
George Capps, M.S., M.B.A.
Director of Business Development
George Capps brings a track record of operational management, business development, and capital-raising success. He previously served as Director of Business Operations at Vasculox (now Tioma Therapeutics) and as Director of Business Development at Mencuro Therapeutics. In all, he has contributed to the raising of well over $30 million in Seed and Series A funding for biopharmaceutical ventures. Prior to these operational roles, Mr. Capps provided management consulting services for biotechnology clients as part of the Strategy & Portfolio Analysis Practice of IMS Health. He received B.S. and M.S. degrees in the Biological Sciences and an M.B.A. from Stanford University.
Robert Beardsley, Ph.D., M.B.A.
Board Member & Business Advisor
Dr. Robert Beardsley brings more than twenty years experience in biotech/pharma, with nearly half of that time spent founding oncology companies and leading them from discovery to the clinic. In addition to his role at Euclises, he is currently Executive Chair of Galera Therapeutics and serves as Chair of Epigenetx. He was previously CEO of Galera, Metabolic Solutions Development Company, Kereos, and Metaphore Pharmaceuticals and has led the advancement of five candidates into and through the clinic. Prior to these roles, he held various positions at Simile Investors, bioStrategies, and Vector Securities. He has served on the boards of numerous biotech/pharmaceutical companies, ranging from pre-seed to public, and raised more than $100M in venture capital support.